Pacira Biosciences
Update in progressPCRX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. develops, manufactures, markets, distributes, and sells non-opioid pain management and regenerative health solutions for U.S. healthcare practitioners. Its products include EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA (triamcinolone acetonide extended-release) for osteoarthritis knee pain, and the iovera system for targeted cryoanalgesia. It is also developing PCRX-201 gene therapy. The company is based in Brisbane, California, and formerly operated as Pacira Pharmaceuticals. It has a NOCITA collaboration with Aratana.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Frank D. Lee
- Founded2006
- Employees825
- Websitewww.pacira.com
Identifiers
- ISINUS6951271005
- FIGIBBG0018FQNS6
- CUSIP695127100
- CIK0001396814